Prosecution Insights
Last updated: November 20, 2026

Crinetics Pharmaceuticals Inc.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Analysis

Crinetics Pharmaceuticals Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners across 2 distinct art units, showing examiner-level distribution within a narrower set of technical examination groups. WELLS, LAUREN QUINLAN is the busiest examiner, with 1 pending matter.

The presence of more examiners than art units makes examiner-specific practice important even where some matters share an art-unit setting. Counsel should compare claim construction and response positions across the files while preserving separate assessments of each examiner’s objections. The matter before WELLS, LAUREN QUINLAN is the identified focal file, but the other assignments may still require distinct amendment and interview planning.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
2
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (50%)
2
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (25%)
§102 only1 (25%)
Double-patenting + other1 (25%)
Multi-statute (no §101)1 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WELLS, LAUREN QUINLAN 1 49.4% +59.5%
MCDOWELL, BRIAN E 1 73.9% +31.4%
BORALSKY, LUKE ALAN 1 57.1% +53.6%
ABDALHAMEED, MANAHIL MIRGHANI ALI 1 50.3% +39.1%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18566887 NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF ABDALHAMEED, MANAHIL MIRGHANI ALI 27d
18541289 CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST BORALSKY, LUKE ALAN —

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18566887 NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF ABDALHAMEED, MANAHIL MIRGHANI ALI 27d
18762266 USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE WELLS, LAUREN QUINLAN —
18587187 PROCESS OF MAKING SOMATOSTATIN MODULATORS MCDOWELL, BRIAN E —
18541289 CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST BORALSKY, LUKE ALAN —

Top Art Units

Art UnitApps
1622 2
1624 2

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18762266 USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE WELLS, LAUREN QUINLAN 1622 §102§103§112DP Non-Final OA — Pending Jul 02, 2024
18587187 PROCESS OF MAKING SOMATOSTATIN MODULATORS MCDOWELL, BRIAN E 1624 §102Other Final Rejection — Pending Feb 26, 2024
18541289 CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST BORALSKY, LUKE ALAN 1624 §101§102§112Other Non-Final OA — Pending Dec 15, 2023
18566887 NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF ABDALHAMEED, MANAHIL MIRGHANI ALI 1622 §103§112 Final Rejection 27d Pending Dec 04, 2023

Managing Crinetics Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Crinetics Pharmaceuticals Inc. have?

Crinetics Pharmaceuticals Inc. has 4 pending office actions as of November 2026, spread across 2 art units and 4 examiners.

Which USPTO examiner handles the most Crinetics Pharmaceuticals Inc. applications?

Lauren Quinlan Wells has the most, with 1 of Crinetics Pharmaceuticals Inc.'s pending office actions.

What technology area are Crinetics Pharmaceuticals Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month